Frontlight ResearchEarly access
Lung cancer trials in Canada
140 of 156 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Halifax, Montreal, Québec, Regina, Saskatoon, Toronto
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Halifax, Hamilton, Montreal, Toronto, Trois-Rivières, Winnipeg
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 3Taking peopleTrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Where
- Chicoutimi, Montreal, Rimouski
- Age
- 18 years and over
- People
- 363 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT06472245 - Phase 3Taking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Abbotsford British Columbia, Montreal, Saint-Jérôme
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - Phase 2/3Taking peopleStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Calgary, Chicoutimi, Montreal, Toronto
- Age
- 18 years and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Edmonton, Toronto
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 3Taking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Chicoutimi, Moncton, Montreal
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - Phase 3Not yet taking people in CanadaBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Where
- Calgary, Greenfield Park
- Age
- 18 years and over
- People
- 550 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT07625644 - Phase 4Taking peopleDabrafenib and/or Trametinib Rollover Study
- Where
- Toronto
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 3Taking peopleLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Edmonton, Montreal, Ottawa, Toronto
- Age
- 18 years and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301 - Phase 3Taking peopleA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Greenfield Park, Montreal
- Age
- 18 years and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00 - Phase 3Active, not recruitingA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Where
- Chicoutimi, Edmonton, Québec, Rimouski
- Age
- 18 years and over
- People
- 530 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00 - Phase 3Taking peopleA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Where
- Montreal, Ottawa, Toronto
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07099898 - Phase 3Taking peoplePhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Where
- Brampton, Halifax, Hamilton, Moncton, Toronto, Vancouver
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00 - Phase 3Not yet taking people in CanadaDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- London, Sault Ste. Marie
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00 - Phase 3Taking peopleStudy of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Where
- Edmonton, Montreal, Regina, Vancouver
- Age
- 18 years and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00 - Phase 3Not yet taking people in CanadaA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Where
- Montreal
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01 - Phase 3Taking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Halifax, Hamilton, Kingston, Montreal, Oshawa, Québec, Toronto
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - No phaseTaking peopleGeneral Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound
- Where
- Québec
- Age
- 18 years and over
- People
- 306 worldwide
- Run by
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
See details and how to joinNCT06950515 - Phase 3Taking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Hamilton, Kingston, Montreal, Ottawa
- Age
- 18 years and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Montreal
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01 - Phase 1/2Taking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Edmonton, Ottawa, Toronto, Vancouver
- Age
- 12 years and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - Phase 1Taking peopleA Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Where
- Toronto
- Age
- 18 years to 99 years
- People
- 600 worldwide
- Run by
- Erasca, Inc.
See details and how to joinNCT06983743 · EU 2026-525794-39-00 - Phase 1/2Taking peopleA Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
- Where
- Toronto
- Age
- 18 years and over
- People
- 315 worldwide
- Run by
- Voronoi, Inc
See details and how to joinNCT07699328 · EU 2025-523122-40-00 - Phase 1/2Taking peopleA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Where
- Montreal, Ottawa, Toronto
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00